Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program
详细信息 查看全文
- 作者：Charles Van Praet ; M.D.a ; charles.vanpraet@uzgent.be" class="auth_mail" title="E-mail the corresponding author ; vanpraetcharles@gmail.com" class="auth_mail" title="E-mail the corresponding author ; Sylvie Rottey ; M.D. ; Ph.D.b ; Fransien Van Hende ; M.D.c ; Gino Pelgrims ; M.D.d ; Wim Demey ; M.D.e ; Filip Van Aelst ; M.D.f ; Wim Wynendaele ; M.D.g ; Thierry Gil ; M.D.h ; Peter Schatteman ; M.D.i ; Bertrand Filleul ; M.D.j ; Dennis Schallier ; M.D. ; Ph.D.k ; Jean-Pascal Machiels ; M.D. ; Ph.D.l ; Dirk Schrijvers ; M.D.m ; Els Everaert ; M.D.n ; Lionel D&rsquo ; Hondt ; M.D.o ; Patrick Werbrouck ; M.D.p ; Joanna Vermeij ; M.D.q ; Jeroen Mebis ; M.D.r ; Marylene Clausse ; M.D.s ; Marika Rasschaert ; M.D.t ; Joanna Van Erps ; M.D.u ; Jolanda Verheezen ; M.D.v ; Jan Van Haverbeke ; M.D.w ; Jean-Charles Goeminne ; M.D.x ; Nicolaas Lumen ; M.D. ; Ph.D.a
- 关键词：Prostatic neoplasms ; Castration-resistant ; Abiraterone acetate ; Compassionate use ; Docetaxel
- 刊名：Urologic Oncology: Seminars and Original Investigations
- 出版年：2016
- 出版时间：June 2016
- 年：2016
- 卷：34
- 期：6
- 页码：254.e7-254.e13
- 全文大小：607 K
文摘
- •
Real-world use of abiraterone acetate appears to be as effective as in clinical trials.
- •
Incidence of severe hypokalemia and anemia is up to 50% higher than expected.
- •
Further evaluation in the pre-docetaxel setting is warranted.